T. Rowe Price Associates
DSGN icon

T. Rowe Price Associates’s Design Therapeutics DSGN Stock Holding History

T. Rowe Price Associates’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
25,606
+9,236
+56% +$115K ﹤0.01% 2759
2026
Q1 		$175K Buy
16,370
+659
+4% +$6.67K ﹤0.01% 2879
2025
Q4 		$148K Sell
15,711
-603
-4% -$4.72K ﹤0.01% 2880
2025
Q3 		$123K Hold
16,314
– – ﹤0.01% 2891
2025
Q2 		$55K Buy
16,314
+3,245
+25% +$12.1K ﹤0.01% 2994
2025
Q1 		$51K Buy
13,069
+618
+5% +$2.95K ﹤0.01% 2927
2024
Q4 		$77K Buy
12,451
+2,167
+21% +$12.5K ﹤0.01% 2881
2024
Q3 		$56K Hold
10,284
– – ﹤0.01% 2914
2024
Q2 		$35K Sell
10,284
-863
-8% -$3.36K ﹤0.01% 2886
2024
Q1 		$45K Buy
+11,147
New +$29.8K ﹤0.01% 2884
2022
Q4 		– Sell
-280,120
Closed -$4.68M – 2945
2022
Q3 		$4.68M Sell
280,120
-72,989
-21% -$1.45M ﹤0.01% 1222
2022
Q2 		$4.94M Sell
353,109
-220,903
-38% -$2.98M ﹤0.01% 1424
2022
Q1 		$9.27M Sell
574,012
-213,653
-27% -$3.27M ﹤0.01% 1377
2021
Q4 		$16.9M Sell
787,665
-661,303
-46% -$11.4M ﹤0.01% 1324
2021
Q3 		$21.3M Hold
1,448,968
– – ﹤0.01% 1278
2021
Q2 		$28.2M Buy
1,448,968
+13,714
+1% +$346K ﹤0.01% 1216
2021
Q1 		$41.9M Buy
+1,435,254
New +$48.4M ﹤0.01% 1064

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's DSGN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Design Therapeutics (DSGN) stake by 56% in Q2 2026, buying an estimated $115K and bringing the position to 25,606 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #2759.

T. Rowe Price Associates first reported a position in DSGN in Q1 2021 and has held it in 17 quarters since. The position peaked at $41.9M in Q1 2021. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • T. Rowe Price Associates held 25,606 shares of Design Therapeutics worth $371K as of Q2 2026.
  • T. Rowe Price Associates bought 9,236 Design Therapeutics shares in Q2 2026, an estimated $115K.
  • Design Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2759 holding.
  • T. Rowe Price Associates first reported a position in Design Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • T. Rowe Price Associates's Design Therapeutics position peaked at $41.9M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.